We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

13 hedge funds and large institutions have $1.43M invested in Evoke Pharma in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

7% less funds holding

Funds holding: 14 → 13 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

53% less capital invested

Capital invested by funds: $3.06M → $1.43M (-$1.63M)

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$480K
2
SOMRS
State of Michigan Retirement System
Michigan
+$365K
3
Renaissance Technologies
Renaissance Technologies
New York
+$321K
4
SM
Sabby Management
Florida
+$203K
5
BFA
BlackRock Fund Advisors
California
+$46.2K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$891K
2
Millennium Management
Millennium Management
New York
-$411K
3
KCM
Knoll Capital Management
Florida
-$381K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$162K
5
UBS Group
UBS Group
Switzerland
-$6.87K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$482K +$480K +1,048 +242%
SOMRS
2
State of Michigan Retirement System
Michigan
$316K +$365K +798 +459%
Renaissance Technologies
3
Renaissance Technologies
New York
$271K +$321K +702 +536%
SM
4
Sabby Management
Florida
$144K +$203K +443 New
California Public Employees Retirement System
5
California Public Employees Retirement System
California
$83K – – –
BFA
6
BlackRock Fund Advisors
California
$60K +$46.2K +101 +120%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$35K – – –
Commonwealth Equity Services
8
Commonwealth Equity Services
Massachusetts
$27K +$38.4K +84 New
Bank of America
9
Bank of America
North Carolina
$4K -$3.2K -7 -35%
BIM
10
BlackRock Investment Management
Delaware
$3K +$1.83K +4 +80%
CPIG
11
Chicago Partners Investment Group
Illinois
$2K +$3.2K +7 New
UBS Group
12
UBS Group
Switzerland
$1K -$6.87K -15 -88%
Morgan Stanley
13
Morgan Stanley
New York
$1K +$1.37K +3 New
OM
14
Opaleye Management
Massachusetts
– -$891K -903 Closed
Millennium Management
15
Millennium Management
New York
– -$411K -417 Closed
KCM
16
Knoll Capital Management
Florida
– -$381K -387 Closed
Bank of New York Mellon
17
Bank of New York Mellon
New York
– -$162K -164 Closed
TRCT
18
Tower Research Capital (TRC)
New York
– -$1K -1 Closed

EVOK Hedge Fund Activity: Q3 2016 in Review

13 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2016, worth a combined $1.43M — down 53% from $3.06M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of EVOK and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.

The largest buyer was Vanguard Group, adding an estimated $480K. The largest seller was Opaleye Management, exiting entirely with an estimated $891K sold.

  • 13 institutional investors held Evoke Pharma (EVOK) as of Q3 2016, down from 14 in Q2 2016.
  • Funds reported $1.43M of Evoke Pharma stock for Q3 2016, down 53% quarter-over-quarter.
  • 4 funds opened new Evoke Pharma positions in Q3 2016 and 5 closed out, a net change of -1 holder.
  • The largest Evoke Pharma buyer in Q3 2016 was Vanguard Group, an estimated $480K added.
  • The largest Evoke Pharma seller in Q3 2016 was Opaleye Management, an estimated $891K sold.

Based on aggregated 13F filings for Q3 2016.